Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology
Presentations will feature 24-week data from a Phase 2 study of ruxolitinib cream in adult patients with vitiligo, which will be highlighted during the late-breaking research session, and 12-week data from a Phase 2 study of ruxolitinib cream in adult patients with atopic dermatitis.
“We look forward to sharing initial results from our Phase 2 study of ruxolitinib cream in vitiligo and additional data from our Phase 2 trial in atopic dermatitis – two conditions for which many patients need novel and effective treatment options,” said
Oral Presentations
12-Week Efficacy and Safety Data of Ruxolitinib Cream in Adult Patients with Atopic Dermatitis: Results from a Phase 2 Study(Session:
Friday, June 14, 2019 at 15:20 –15:30 p.m. CET , Room Yellow 3
Efficacy and Safety of Ruxolitinib Cream for the Treatment of Vitiligo: Results of a 24-Week Randomized, Double-Blind, Dose-Ranging, Vehicle-Controlled Study (Session:
Saturday, June 15, 2019 at 9:25 –9:35 a.m. CET , Room Yellow 3
Full session details and data presentation listings for WCD 2019 can be found at: https://www.wcd2019milan.org/scientific-programme/.
Conference Call Information
To access the conference call on
If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for
About
For additional information on
Follow @
Forward Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s development pipeline and whether or when any development compounds will be approved for use in humans anywhere in the world, its presentation plans for the upcoming WCD annual meeting and its goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements. These forward-looking statements are based on the Company’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments and the risks related to the efficacy or safety of the Company’s development pipeline, the results of further research and development, the high degree of risk and uncertainty associated with drug development, clinical trials and regulatory approval processes, other market or economic factors and competitive and technological advances; and other risks detailed from time to time in the Company’s reports filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190520005230/en/
Source:
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Michael Booth, DPhil
+1 302 498 5914
mbooth@incyte.com